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Abstract
Background:  Xenobiotic Metabolizing Enzymes (XMEs) contribute to the detoxification of
numerous cancer therapy-induced products. This study investigated the susceptibility and
prognostic implications of the CYP2E1, CYP2C19, CYP2D6, mEH and NAT2 gene polymorphisms
in breast carcinoma patients.
Methods:  The authors used polymerase chain reaction and restriction enzyme digestion to
characterize the variation of the CYP2E1, CYP2C19, CYP2D6, mEH and NAT2 gene in a total of
560 unrelated subjects (246 controls and 314 patients).
Results: The mEH (C/C) mutant and the NAT2 slow acetylator genotypes were significantly
associated with breast carcinoma risk (p = 0.02; p = 0.01, respectively). For NAT2 the association
was more pronounced among postmenopausal patients (p = 0.006). A significant association was
found between CYP2D6 (G/G) wild type and breast carcinoma risk only in postmenopausal
patients (p = 0.04). Association studies of genetic markers with the rates of breast carcinoma
specific overall survival (OVS) and the disease-free survival (DFS) revealed among all breast
carcinoma patients no association to DFS but significant differences in OVS only with the mEH gene
polymorphisms (p = 0.02). In addition, the mEH wild genotype showed a significant association with
decreased OVS in patients with axillary lymph node-negative patients (p = 0.03) and with
decreasesd DFS in patients with axillary lymph node-positive patients (p = 0.001). However, the
NAT2 intermediate acetylator genotype was associated with decreased DFS in axillary lymph node-
negative patients.
Conclusion: The present study may prove that polymorphisms of some XME genes may predict
the onset of breast carcinoma as well as survival after treatment.
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Background
Breast carcinoma is the most frequent malignancy in
women [1] and represents the second leading cause of
cancer death among women (15% of cancer deaths) [2].
With 200,000 cases in the U.S.A. (27% of all cancers in
women) [3]; 320,000 cases in Europe (31% of all cancers
in women) [4] and one million new cases diagnosed
worldwide every year, breast carcinoma is still a major
health problem in many developed countries. In Tunisia,
breast carcinoma accounts for 20–25% of malignant
tumors in women with an annual incidence of about
800–1000 cases [5]. The etiology of breast carcinoma is
still poorly understood in spite of known breast carci-
noma risk factors such as age, reproductive events
(menarche, menopause, pregnancy, breastfeeding), exog-
enous hormones (hormone replacement therapy and oral
contraceptives), lifestyle and environment risk factors
(pollution, alcohol, diet, obesity), ionizing radiation,
chemo preventive agents, as well as genetic factors (high-
and low penetrance breast cancer susceptibility genes) [6].
In hereditary breast carcinoma, mutations in highly pene-
trant genes such as BRCA1 or BRCA2 confer a relatively
high risk for developing breast carcinoma, though this risk
accounts only for about 5 to 10% of all breast carcinoma
cases [7]. It is suggested that the effect of low penetrance
cancer susceptibility genes modulated by environmental
exposure and lifestyle factors are likely to account for most
of sporadic breast carcinoma cases [8]. In the latters, the
proportion of breast carcinoma attributable to such
genetic traits, in combination with environmental expo-
sure, is likely to be much higher than the hereditary pro-
portion and accounts for 90 to 95% of all breast
carcinoma cases [8].
Candidate genes of low-penetrance breast carcinoma sus-
ceptibility include those encoding for Xenobiotic Metabo-
lizing Enzymes (XMEs) involved in carcinogen
metabolism and detoxification [9]. These XMEs can be
divided into phase I enzymes (Cytochrome P450 family:
CYP2E1, CYP2C19, CYP2D6 and mEH) that metaboli-
cally activate potentially carcinogenic forms and phase II
enzymes (N-acetyl- and gluthatione-S-transferases fami-
lies: NAT1, NAT2, GSTT1, GSTM1 and GSTP1) that meta-
bolically inactivate carcinogens to increase its solubility in
such a way as to facilitate its excretion and detoxification
[10]. XMEs are also involved in the metabolism of a wide
range of drugs including a variety of anticancer chemo-
therapy agents. These agents exert their anti-neoplastic
effects by generating reactive oxygen species (ROS) whose
direct cytotoxic effects are in many cases the proximate
cause of tumor cell death and are likely to have initial and
immediate impact on treatment efficacy [11]. Further-
more, altered intratumoral genes coding for XMEs were
suggested as a potential molecular mechanism to explain
metabolism's alteration of the chemotherapy agents and
consequently the reduced treatment efficacy and tumor
resistance [12].
Polymorphisms in both phase I and phase II enzyme
genes may result in alteration of their expression, function
and activity. Several studies have attempted to tackle the
genetic polymorphisms of different XMEs alone or in
combinations with altered risks of breast carcinoma
[9,10]. Moreover, because of the great number of carcino-
gen-activating and detoxifying enzymes, the complexity of
exposures to environmental carcinogens and gene-gene
interactions, evaluating a single polymorphic enzyme
may not be sufficient to assess their role in carcinogenesis.
However, accumulating series of alleles "at risk" consider-
ably increase the cancer risk.
The present study first investigated the relationship
between DNA variants in Cytochrome P 450 (CYP) -2E1,
-2C19, -2D6, microsomal Epoxide Hydrolase (mEH) and
N-acetyltransferase -2 (NAT2) enzymes and susceptibility
to breast carcinoma. Then the potential contribution of
the combined multilocus genotypes in breast carcinoma
susceptibility was examined. Finally, the study tried to
establish a potential association of these gene variations
with tumor clinical-pathological characteristics, with sur-
vival and relapse after treatment from breast carcinoma.
Methods
Subjects
A total of 560 unrelated subjects (246 controls and 314
patients), living in Sousse on the middle coast of Tunisia,
were enrolled in this study. Clinical data about the cohort
of the 314 patients recruited from the department of Radi-
ation Oncology and Medical Oncology of Sousse Hospi-
tal, were collected between 1994 and 2002. All patients
included in this study had primary breast carcinoma, with
unilateral breast tumors. The patients had a mean age of
52 ± 24 years. The median follow-up was 36 months
(range, 1 to 120 months). At the time of analysis, 76
patients relapsed (local or distant recurrence). Among
them, 36 patients died from breast carcinoma (47.3%). A
detailed description of the clinical pathological character-
istics of this cohort was summarized in Table 1 and
reported elsewhere [5,13]. Control subjects having a
mean age of 41 ± 14 years, were healthy blood donors
having no evidence of any personal or family history of
cancer or other illnesses. Written informed consent was
obtained from all subjects.
Genomic DNA extraction
Genomic DNA was extracted from peripheral blood leu-
kocytes by a salting procedure [14]. Briefly, 10 ml of
blood were mixed with triton lysis buffer (0.32 M sucrose,
1% Triton X-100, 5 mM MgCl2, H2O, 10 mM Tris-HCl, pHBMC Cancer 2008, 8:109 http://www.biomedcentral.com/1471-2407/8/109
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7.5). Leukocytes were spun down and washed with H2O.
The pellet was incubated with proteinase K at 56°C and
subsequently salted out at 4°C using a concentrated NaCl
solution. Precipitated proteins were removed by centrifu-
gation. The DNA in supernatant fluid was precipitated
with ethanol. The DNA pellet was dissolved in 400 μl of
sterile distilled water.
Polymorphism analysis
Polymorphic sites of the mEH (T348C), CYP2E1 (C-
1091T), CYP2C19 (intron 4/exon 5 G-A splice site muta-
tion), CYP2D6 (G1934A), NAT2 (C481T, G590A, A803G
and G857A) genes were genotyped by Polymerase Chain
Reaction-Restriction Fragment Length Polymorphism
(PCR-RFLP) assay. Previously reported primers and
restricted enzymes in RFLP-PCR are listed in Table 2. All
PCR reactions were performed in an independent blinded
duplicate manner and for each polymorphism some sam-
ples were confirmed by sequencing the PCR products (Abi
Prism 310, Applied Biosystems).
The polymorphic site of the mEH (T348C) and CYP2E1
(C-1091T) genes was simultaneously revealed by Multi-
plex Polymerase Chain Reaction (PCR)-Restriction Frag-
ment Length Polymorphism (RFLP) assay described by
Salama et al. with a slight modification [15]. A multiplex
PCR reaction was performed in a total volume of 50 μl
containing 100 ng of genomic DNA, 200 μmol dNTPs, 2
mM MgCl2, 1 × Taq polymerase buffer, 100 pmol of
CYP2E1 (X3, X4) and mEH (X5, X6) primers and 1 U of
Taq DNA polymerase (Amersham, Paris, France). The
reaction conditions used with the thermal cycler (Biome-
tra, Göttingem, Germany) were as follows: the initial
incubation at 94°C for 5 min, followed by 35 cycles of
incubation at 94°C for 2 min; 59°C for 1 min, and 72°C
for 1 min and achieved by a final incubation at 72°C for
10 min. To verify proper amplification conditions, 10 μl
of PCR product were analyzed on a 2% agarose gel and
stained with ethidium bromide, the amplification of
CYP2E1 and mEH was revealed by the presence of bands
at 410 and 231 bp, respectively. To detect CYP2E1 (C-
1091T) and mEH (T348C) polymorphisms, amplified
DNA was digested with 10 U of PstI (37°C, 3 h) and Tth
111I (65°C, 3 h) endonucleases respectively. CYP2E1
wild type allele was characterized by the absence of PstI
restriction site and revealed by a band at 410 bp. The
mutant allele was characterized by the presence of PstI
restriction site and revealed by a band at 290 bp and a
band at 120 bp. Tth 111I digestion produced 209 and 22
bp size fragments for mEH mutant allele, whereas the
mEH wild type allele remained undigested (231 bp).
The splice-site mutation of CYP2C19 (G-A, exon 5) was
analyzed by PCR-RFLP assay described by De Morais et al.
with some modifications [16]. PCR incubation was per-
formed in a total volume of 20 μl containing 200 ng of
genomic DNA, 200 μmol dNTPs, 1.5 mM MgCl2, 1 × Taq
polymerase buffer, 0.25 μmol of CYP2C19 (X1, X2) prim-
ers and 1 U of Taq DNA polymerase. Amplification was
done with one pretreatment cycle at 94°C for 4 min, 55°C
for 2 min and 72°C for 1 min, followed by 30 cycles with
0.5 min denaturation (94°C), 1 min annealing (55°C)
and 1.5 min elongation (72°C), achieved by a 5 min final
elongation (72°C). This yielded a 169 bp fragment.
Restriction enzyme cleavage was performed overnight on
10  μl of PCR product after addition of 10 U of SmaI
restriction enzyme. The SmaI digestion produced frag-
ments of 120 and 49 bp for CYP2C19 wild type allele;
whereas the mutant allele remains undigested (169 bp).
Table 1: Clinical features of breast carcinoma patients
Variables Pourcentage (%)
Clinical tumor size
T1–T2 62.28
T3–T4 37.72
Lymph node status
N(-) 54.2
N(+) 69.12
SBR grading
1 – 2 80.88
38 6 . 7 6
Table 2: Primers and restriction enzymes used for polymorphism genotyping.
Genes Polymorphisms Primers Restriction enzymes References
mEH T348C Sens : 5' CTT GAG CTC TGT CCT TCC CAT CCC 3' Tth 111I 15
Antisens : 5' AAT CTT AGT CTT GAA GTG ACG GT 3'
CYP2E1 C-1091T Sens : 5' CCA GTC GAG TCT ACA TTG TCA 3' PstI 15
Antisens : 5' TTC ATT CTG TCT TCT AAC TGG 3'
CYP2C19 Intron4/exon5 G-A splice mutation Sens : 5' AAT TAC AAC CAG AGC TTG GC 3' SmaI 16
Antisens : 5' TAT CAC TTT CCA TAA AAG CAA G 3'
CYP2D6 G1934A Sens : 5' GCT TCG CCA ACC ACT CCG 3' BstN1 17
Antisens: 5' AAA TCC TGC TCT TCC GAG GC 3'
NAT2 C481T, G590A, A803G, G857A Sens : 5' GCT GGG TCT GGA AGC TCC TC 3' KpnI, TaqI, DdeI, BamHI 17
Antisens : 5' TTG GGT GAT ACA TAC ACA AGG G 3'BMC Cancer 2008, 8:109 http://www.biomedcentral.com/1471-2407/8/109
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A PCR-RFLP method described by Lemos et al. with a
slight modification was used for the detection of the
CYP2D6 G1934A mutation [17]. Amplification was car-
ried out in a 20 μl reaction volume containing 200 ng of
genomic DNA, 200 μmol dNTPs, 1.5 mM MgCl2, 1 × Taq
polymerase buffer, 150 ng of each primer (Pc1, Pc2) and
1 U of Taq DNA polymerase. A 334 bp fragment was
amplified after an initial denaturation at 94°C for 5 min
and 30 cycles with 1 min denaturation (94°C), 1 min
annealing (60°C) and 2 min elongation (72°C), followed
by 5 min final elongation (72°C). Digestion of 10 μl of
the PCR product was carried out with 5 U of the restriction
enzyme BstN1 (60°C, 1 h). CYP2D6 wild-type allele was
identified by the presence of 230 and 104 bp size frag-
ments. CYP2D6 mutant allele did not have a BstN1
restriction site and remained undigested (334 bp).
The four most common NAT2 single nucleotide polymor-
phisms (C481T, G590A, A803G and G857A) associated
with low NAT2 activity were genotyped using a modified
version of PCR-RFLP described by Lemos et al. [17].
Essentially as published, aliquots of 100 ng of genomic
DNA were amplified in a 60 μl reaction volume contain-
ing 400 μmol dNTPs, 1.5 mM MgCl2, 1 × Taq polymerase
buffer, 100 ng of each primer (Pn1, Pn2) and 1 U of Taq
DNA polymerase. After an initial denaturation at 94°C for
5 min, 34 cycles were performed consisting of denatura-
tion at 94°C for 0.5 min, annealing at 60°C for 0.5 min
and elongation at 72°C for 0.75 min, completed with a
final cycle of 60°C for 5 min and 72°C for 5 min. This
resulted in the amplification of a 540 bp fragment. Subse-
quently, 10 μl of this reaction were then subjected to
restriction enzyme analysis with 5 U of KpnI, TaqI, DdeI
and BamHI for the detection of mutations C481, G590A,
A803G and G857A, respectively. The wild-type allele
(NAT 2 *4) was identified by complete digestion by KpnI,
TaqI and BamHI, but not DdeI. The mutations either
destroyed the recognition sites of the first three enzymes
or created a new one for the fourth. NAT 2 *5A, *6B, *7A
and *12A alleles were identified by the presence of
C481T, G590A, G857A and A803G mutations respec-
tively. The NAT 2 *5B allele was identified by the presence
of both C481T and A803G mutations. Restriction
enzymes were obtained from New England BioLabs.
Digestion conditions were performed according to the
manufacturer's instructions and summarized in Table 3.
Digestion products were separated at the appropriate con-
centrations on a 2, 3 or 4% Low-melting point agarose gel
and stained with ethidium bromide.
Statistical analysis
The genotype frequencies of different genes were tested for
Hardy-Weinberg equilibrium for both patient and control
groups using the χ2 test. The same test was used to evalu-
ate significant associations between the disease (breast
carcinoma versus controls) and different genotypes. The
differences were considered significant if the P-value did
not exceed 0.05. Odd ratios (ORs) and 95% confidence
intervals (CIs) were calculated by unconditional logistic
regression. When expected values in contingency tables
were under 5, Fisher's exact test was used.
The clinical pathological parameters studied herein were
age, nodal status, SBR (Scraff, Bloom and Richardson)
tumor grade, clinical tumor size and response to treat-
ment. The clinical pathological parameters were dichot-
omised as follows: Age (<50 years versus ≥ 50 years), nodal
status (≥ 1 versus no positive lymph node), SBR tumor
grade (1–2 versus  3), clinical tumor size (T1–T2 versus
T3–T4).
Disease-free survival (DFS) was defined as the time from
the date of diagnosis to the first local or distant recurrence
or to the last contact. Breast carcinoma-specific overall
survival (OVS) was defined as the time from the date of
diagnosis to death if the patient died from breast carci-
noma or to the last contact. Six-year survival rates were
estimated, and survival curves were plotted according to
Kaplan and Meier. Differences between groups were calcu-
lated by the log-rank test.
Statistics were performed using SEM-STATISTIQUES soft-
ware (Centre Jean Perrin, Clermont-Ferrand, France).
Results
XMEs gene polymorphisms and susceptibility to breast 
carcinoma
The number of polymorphism-genotyped individuals was
dependent upon DNA availability. All genotype distribu-
tions did not diverge significantly from Hardy-Weinberg
Table 3: Restriction enzyme conditions used for NAT2 polymorphism genotyping.
Polymorphisms Restriction Enzymes Temperature and incubation time Fragment size (pb) Agarose (%)
C481T KpnI (5 U) 37°C – 4 h 30 114 + 426 2
G590A TaqI (5 U)* 65°C – 1 h 30 223 + 170 + 147 3
A803G DdeI (5 U)** 37°C – 4 h 30 65 + 346 + 25 + 104 4
G857A BamHI (5 U) 37°C – 4 h 30 490 + 50 2
* two sites; ** three sites of restriction enzymesBMC Cancer 2008, 8:109 http://www.biomedcentral.com/1471-2407/8/109
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equilibrium for both patient and control groups sepa-
rately. There were no significant differences between
patients and controls in the genotype frequencies for
CYP2C19, CYP2E1 and CYP2D6 genes (Table 4). When
the patients were stratified according to their menopause
status, the CYP2D6 (G/G) wild genotype frequency was
found to be significantly higher in postmenopausal
patients than in controls (OR = 1.79; p = 0.04), suggesting
an association between the homozygous CYP2D6 wild
genotype and the late onset of breast carcinoma. How-
ever, the heterozygous CYP2D6 (G/A) genotype was asso-
ciated with a protective effect against breast carcinoma
(OR = 0.5; p = 0.02) in postmenopausal patients. A statis-
tically significant association was found between mEH
mutant homozygous genotype (C/C) and breast carci-
noma in Tunisians (OR = 2.06; p = 0.02). This association
seems to be particularly higher in premenopausal patients
(OR = 2.3; p = 0.01).
Genotyping analysis of NAT2 polymorphisms revealed 17
different genotypes resulting from the combinations of
the following 6 alleles: NAT 2 *4 (wild-type), *5A, *5B,
*6B, *7A and *12A (mutants). Only NAT2*4 and *12A
alleles represented rapid acetylators while the other alleles
represented slow ones (Table 3). Among the 17 geno-
types, the heterozygous slow acetylators NAT2*5A/*6B
were found to be statistically significant as a risk factor for
breast carcinoma (Table 5). Heterozygous NAT2*12A/
Table 4: CYP2E1, CYP2C19, CYP2D6, mEH and NAT2 genotype frequencies in control subjects and in patients with breast 
carcinoma.
Genotypes Controls All Patients Premenopausal Patients Postmenopausal Patients
n f n f P OR (95%CI) n f pO R  ( 9 5 % C I )n f p OR (95%CI)
CYP2E1 
(C-1091T)
244 304 192 111
CYP2E1 (C/C) 232 0.95 296 0.97 N.S 1.91(0.72–5.22) 186 0.97 N.S 1.6(0.55–4.89) 109 0.98 N.S 2.82 
(0.58–18.57)
CYP2E1 (C/T) 12 0.05 08 0.03 N.S 0.52(0.19–1.4) 06 0.03 N.S 0.62(0.2–1.83) 02 0.02 N.S 0.35 
(0.05–1.71)
CYP2E1 (T/T) 00 0.00 00 0.00 N.S - 00 0.00 N.S - 00 0.00 N.S -
CYP2C19 
(exon5 G-A)
240 304 193 109
CYP2C19 (G/G) 197 0.822 239 0.787 N.S 0.8(0.51–1.26) 155 0.804 N.S 0.89(0.53–1.49) 83 0.762 N.S 0.7 
(0.39–1.25)
CYP2C19 (A/G) 41 0.170 61 0.200 N.S 1.22(0.77–1.93) 37 0.191 N.S 1.15(0.68–1.94) 23 0.211 N.S 1.30
(0.71–2.38)
CYP2C19 (A/A) 02 0.008 04 0.013 N.S 1.59(0.25–12.56) 01 0.005 N.S 0.62(0.02–8.76) 03 0.027 N.S 3.37
(0.45–29.24)
CYP2D6 
(G1934A)
230 300 189 109
CYP2D6 (G/G) 167 0.726 235 0.783 N.S 1.36(0.9–2.07) 145 0.767 N.S 1.24(0.78–1.99) 90 0.827 0.04 1.79
(0.97–3.31)
CYP2D6 (G/A) 56 0.243 58 0.193 N.S 0.74(0.48–1.15) 41 0.217 N.S 0.86(0.53–1.42) 15 0.137 0.02 0.5 
(0.25–0.96)
CYP2D6 (A/A) 07 0.031 07 0.023 N.S 0.76(0.24–2.48) 03 0.016 N.S 0.51(0.1–2.24) 04 0.036 N.S 1.21
(0.29–4.74)
mEH (T348C) 244 306 194 110
mEH1 (Tyr/Tyr) 113 0.463 149 0.486 N.S 1.1(0.77–1.56) 97 0.500 N.S 1.16(0.78–1.72) 52 0.472 N.S 1.04 
(0.65–1.67)
mEH2 (Tyr/His) 115 0.471 119 0.388 N.S 0.71(0.5–1.02) 70 0.360 0.02 0.63(0.42–0.95) 47 0.427 N.S 0.84 
(0.52–1.35)
mEH3 (His/His) 16 0.065 38 0.124 0.02 2.02(1.06–3.89) 27 0.139 0.01 2.3(1.15–4.64) 11 0.1 N.S 1.58 
(0.66–3.77)
NAT2 237 290 184 105
Rapid 
Acetylators
14 0.059 24 0.082 N.S 1.44(0.69–3) 18 0.097 N.S 1.73(0.79–3.79) 06 0.057 N.S 0.97
(0.32–2.79)
Intermediate 
Acetylators
105 0.443 92 0.317 N.S 0.58(0.4–0.85) 61 0.331 N.S 0.62(0.41–0.95) 30 0.285 0.006 0.52
(0.3–0.85)
Slow 
Acetylators
118 0.497 174 0.600 0.01 1.51(1.05–2.17) 105 0.570 N.S 1.34(0.89–2.01) 69 0.657 0.006 1.93 
(1.17–3.2)
The chi-square test was used to determine whether significant differences (p value) were observed when the patient group was compared with the 
control group. f, frequencies; NS: not significant.BMC Cancer 2008, 8:109 http://www.biomedcentral.com/1471-2407/8/109
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*5B genotype (intermediate acetylator) was significantly
more frequent in controls than in patients (8.86% vs
2.41%) indicating a protective effect of this gene variant
against breast carcinoma (OR = 0.25, p = 0.001). When
the 17 genotypes were pooled according to their acetylator
status, the only significant difference was in the frequency
of NAT2 slow acetylator genotype, which was higher in
patients than in controls (60% vs 49.7%). Thus, NAT2
slow acetylator genotype was significantly associated with
breast carcinoma risk (Table 4). This association was more
pronounced among postmenopausal patients (OR = 1.93,
p = 0.006). However, a significant association with a pro-
tective effect in postmenopausal patients can be assigned
to NAT2 intermediate acetylator genotype (OR = 0.52, p =
0.006).
A combined genotype analysis revealed that mEH (C/C)-
NAT2 slow acetylator genotype combinations was associ-
ated with breast carcinoma risk (OR = 2.18; p = 0.04). The
distribution of this genotype combination was 3.79% in
controls and 7.93% in patients. Conversely, the mEH (C/
T)-NAT2 (Rapid/Slow acetylators) combination was
highly associated with a protective effect against breast
carcinoma (OR = 0.44; p = 0.0004).
Survival analysis and prognostic significance of XME gene 
polymorphisms
When the relationship between the distribution of
CYP2E1, CYP2C19, CYP2D6 and NAT2 genotypes in all
patients and the survival (OVS or DFS) was tested, no sig-
nificant differences were observed between the different
Kaplan-Meier survival curves. However, mEH wild
homozygous genotype (Tyr/Tyr) was significantly associ-
ated with decreased breast carcinoma specific overall sur-
vival (Fig. 1) but not Disease-free survival. The estimated
6-year OVS rate in the groups of patients carrying or not
the mEH wild homozygous genotype (Tyr/Tyr) was
79.41% and 89.7%, respectively (log-rank test, p = 0.02).
Further analyses were conducted to explore whether the
studied gene polymorphisms were associated with sur-
vival among different subgroups of patients (Age, nodal
status, SBR tumor grade, clinical tumor size). The only sig-
nificant associations were found with axillary lymph
node-negative or -positive patients. Indeed, the overall
survival was significantly shorter in axillary lymph node-
negative patients carrying the mEH wild homozygous
genotype (Tyr/Tyr). The 6-year OVS rate in the groups of
patients carrying or not mEH wild genotype was 85.29%
and 97.05%, respectively (log-rank test, p = 0.03) (Fig. 1).
In addition, statistical significant differences in DFS were
seen between patients axillary lymph node-positive carry-
ing the mEH wild homozygous genotype (Tyr/Tyr) and
those without (log-rank test, p = 0.001). The group of
patients with mEH wild homozygous genotype (Tyr/Tyr)
had lower breast carcinoma disease free-survival than
those without mEH wild genotype. The 6-year DFS rates
were 16.2% and 60.3%, respectively (Fig. 2).
Still among the axillary lymph node-negative patients,
when a DFS comparison was made between patients who
had NAT2 intermediate acetylator genotype and those
who did not, an increase in DFS was observed in patients
carrying NAT2 intermediate acetylator genotype (log-rank 
Table 5: NAT2 Genotype Frequencies in Control Subjects and in Patients with Breast Carcinoma.
NAT2 genotypes Controls (n = 237) All Patients (n = 290) p OR (95%CI)
nn
NAT2*4/4 13 23 NS 1.48(0.7–3.18)
NAT2*4/12A 01 00 NS* -
NAT2*12A/12A 00 01 NS* -
NAT2*4/5A 01 07 NS* -
NAT2*4/5B 41 45 NS 0.88(0.54–1.43)
NAT2*4/6B 32 27 NS 0.66(0.37–1.17)
NAT2*4/7A 05 04 NS* -
NAT2*12A/5B 21 07 0.001 0.25(0.1–0.65)
NAT2*12A/6B 05 02 NS* -
NAT2*5A/5B 02 04 NS* -
NAT2*5A/6B 00 05 0.04*-
NAT2*5A/7A 00 01 NS* -
NAT2*5B/5B 35 53 NS 1.29(0.79–2.11)
NAT2*5B/6B 54 68 NS 1.04(0.68–1.59)
NAT2*5B/7A 06 11 NS 1.52(0.51–4.69)
NAT2*6B/6B 15 25 NS 1.40(0.69–2.86)
NAT2*6B/7A 06 07 NS 0.95(0.28–3.24)
The chi-square test was used to determine whether significant differences (p value) were observed when the patient group was compared with the 
control group. NS: not significant; *: Fisher test was used.BMC Cancer 2008, 8:109 http://www.biomedcentral.com/1471-2407/8/109
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Breast carcinoma-specific overall survival (OVS) of breast carcinoma patients according to the presence or absence of the mEH  wild type genotype; (A) among the whole breast carcinoma patients and (B) among axillary's lymph node-negative ones Figure 1
Breast carcinoma-specific overall survival (OVS) of breast carcinoma patients according to the presence or 
absence of the mEH wild type genotype; (A) among the whole breast carcinoma patients and (B) among axil-
lary's lymph node-negative ones. p denotes the log-rank test value.
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test, p = 0.04). The 6-year DFS rate in the group of patients
with NAT2 intermediate acetylator genotype was 89.7%
and 63.3% in patients without this genotype (Fig. 3).
There were no statistically significant associations
between all the five gene polymorphisms and the rest of
clinical pathological parameters such as clinical response
to chemotherapy, tumor grade and clinical tumor size
analyzed in our study.
Discussion
The CYP2D6 polymorphism analysis revealed that the
homozygous wild type genotype increased susceptibility
to breast carcinoma in the selected population of post-
menopausal patients, however controversial results were
reported. Indeed, De Jong et al. found that homozygous
mutant CYP2D6 genotype increased the risk of breast car-
cinoma [18]. In the selected population, the heterozygous
CYP2D6 genotype was also found to be associated to a
protective effect against breast carcinoma. Conversely,
Ladona et al. reported a significant association between
the heterozygous CYP2D6 genotype and breast carcinoma
risk among postmenopausal patients [19]. More recently,
an association with a protective effect against papillary
thyroid cancer has been found with the homozygous
mutant CYP2D6 genotype and similar results have been
reported for tumors at other sites, such as lung cancer and
leukaemia [17,20,21]. The CYP450 enzymes, including
CYP2D6, are responsible for the activation of procarcino-
gens and genotoxic metabolites [22]. The CYP2D6 poly-
morphism G1934A leads to a disruption of the reading
frame and a truncated non functional protein [23,24].
Therefore, individuals with heterozygous or mutant
homozygous CYP2D6 genotypes have poor or no enzyme
activity respectively. This decreases the formation of gen-
otoxic metabolites and reduces the onset of breast carci-
noma development. However, individuals carrying two
copies of CYP2D6 wild type allele have higher enzyme
activity than those having one or no copy of the wild type
allele. Wild homozygous CYP2D6 genotype will metabo-
lize more carcinogens to their genotoxic metabolites [24].
Thus, this higher enzyme activity probably increases DNA
damage levels and consequently the risk of breast carci-
noma.
Regarding hormone-associated tumors such as ovarian,
cervical or prostate cancers, many conflicting data have
been found but without conclusive links to CYP450
genes. In this field, numerous studies conducted on differ-
ent populations and ethnic groups have indicated the
absence of a major impact of the CYP2D6, CYP2C19 and
CYP2E1 genes in cancer risk [25]. These previous findings
are in accordance with ours which demonstrate the
absence of any association between CYP2C19 and
CYP2E1 gene polymorphisms with breast cancer. In addi-
tion, when compared with the allele frequencies of the
CYP2D6, CYP2C19 and the CYP2E1 genes in Italian, Por-
tuguese and Egyptian populations, we found similar fre-
Breast carcinoma-specific disease-free survival (DFS) of axillary's lymph node-positive breast carcinoma patients according to  the presence or absence of the mEH wild type genotype Figure 2
Breast carcinoma-specific disease-free survival (DFS) of axillary's lymph node-positive breast carcinoma 
patients according to the presence or absence of the mEH wild type genotype. p denotes the log-rank test value.
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quencies in healthy Tunisian individuals [20,26-28].
However, the previous findings can not be generalized
even with similarities between healthy individuals.
Indeed, it was found in the Portuguese population that
the CYP2E1 gene could be associated with prostate cancer
risk [29]. Therefore, the study of candidate gene associa-
tions to cancer susceptibility has been made difficult due
to the different ethnic origins and lifestyle of the study
groups. This is particularly true in the case of CYP450
enzyme genes which may influence the carcinogenesis
pathway and where environmental factors are relevant
and make such comparisons more difficult. Further stud-
ies are likely to detect much stronger associations of can-
cer susceptibility with CYP450 genes taking into account
ethnicity and different environmental risk factors.
The current study suggests a significant association
between the mEH homozygous mutant genotype and the
risk of breast carcinoma, especially, among the subgroup
of premenopausal patients. The heterozygous mEH geno-
type was also found to be protective against breast carci-
noma in the selected population. The genetic
polymorphism T348C of mEH leads to a substitution of
Tyrosine (Tyr) residue 113 by Histidine (His) that is
known to decrease the enzyme activity [30]. Thus,
"His113" poor activity genotype was responsible for defi-
cient detoxification, accumulation of genotoxic metabo-
lites and probably breast carcinoma initiation. In contrast,
the presence of at least one "Tyr113" high activity allele
was sufficient to detoxify genotoxic metabolites, thereby
protecting breast cells against DNA damage and breast
carcinoma risk. Nevertheless, several studies have indi-
cated that the high activity Tyr113 genotype has been
associated with increased risk for lung and upper aero-
digestive tract cancer [31,32]. In addition, studies con-
ducted in relation to ovarian cancer provide evidence
against substantial increased risk associated with mEH
polymorphisms [33].
For NAT2, the alleles NAT2*5A and B, NAT2*6B and
NAT2*7A observed in our study and respectively corre-
sponding to the Ile114Thr, Arg197Gln and Gly286Glu
substitutions, were associated with slow phenotype [34].
However, the allele NAT2*12A resulting from Lys268Arg
substitution produced an enzyme with an acetylating
capacity similar to the wild type rapid acetylator NAT2*4
allele [34]. Furthermore, individuals carrying one copy of
rapid acetylator allele and one copy of slow acetylator
allele had an intermediate phenotype [34]. The NAT2
enzyme has been detected in human breast cells. Several
studies have indicated that the level of DNA adducts in
breast tissues is higher among individuals with the slow
NAT2 acetylator genotype, suggesting that slow NAT2
acetylators are more susceptible to adduct-induced DNA
Breast carcinoma-specific disease-free survival (DFS) of axillary's lymph node-negative breast carcinoma patients according to  the presence or absence of the NAT2 intermediate acetylator genotype Figure 3
Breast carcinoma-specific disease-free survival (DFS) of axillary's lymph node-negative breast carcinoma 
patients according to the presence or absence of the NAT2 intermediate acetylator genotype. p denotes the log-
rank test value.
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damage, which may subsequently contribute to higher
risk of breast carcinoma [35]. These findings reinforce our
results indicating that individuals who are slow acetylator
have increased risk of breast carcinoma. This association
was more pronounced among postmenopausal patients.
Indeed, slow acetylators have a reduced rate of metabo-
lism of aromatic and heterocyclic amines, and presuma-
bly in these individuals, arylamines shift towards the
hydroxylation pathway which forms DNA reactive metab-
olites [35]. Since slow acetylators may be at higher risk of
adduct-induced DNA damage, they have an increased sus-
ceptibility to breast carcinogenesis. Unlikely, Alberg et al.
reported that NAT2 rapid acetylator genotype was associ-
ated with increased breast carcinoma risk especially
among postmenopausal patients [35], indicating that
NAT2 was acting more as an activator of procarcinogens
than as a detoxifier [35]. This association should be care-
fully viewed given the very small number of homozygous
NAT2 rapid acetylators and the association has not been
seen in other studies. For instance, in Taiwanese breast
cancer cases it was found that breast cancer risk was not
significantly influenced by NAT2 polymorphisms [36]. In
addition, studies which attempted to investigate the NAT2
genetic polymorphisms as an independent risk marker for
breast carcinoma have failed [37]. Like CYP450 genes,
association studies of NAT2 gene polymorphisms to other
hormone-associated tumors are inconsistent. NAT2 may
have conflicting associating results for cancer risk in the
same population. In fact, slow acetylator genotype was
found to have protective and susceptibility effects against
prostate and cervical cancer respectively [38,39].
The discrepancy between results, including ours, which
tried to address the role of XME gene polymorphisms as
risk factors in cancers, particularly breast carcinoma, may
be due to several confounding factors including differ-
ences in ethnicity of the analyzed populations, sample
size, the type of environmental carcinogens to which dif-
ferent population are exposed and the simultaneous
involvement of a large number of XME variants.
In this study, mEH gene polymorphism was also associ-
ated with the early onset of breast carcinoma whereas pol-
ymorphisms in NAT2 and CYP2D6 genes are also
correlated with late onset of breast carcinoma. These find-
ings indicate that the penetrance of XME genes varies
according to the time of onset of breast carcinoma. This
suggests that there could be some new contributing fac-
tors, most likely environmental, affecting the penetrance
and phenotype expression of XME gene polymorphisms.
Indeed, this influence was mostly proposed in certain
studies, especially those conducted on hereditary breast
carcinoma related to BRCA1/2 genes [40]. This partly
explains the emergence of genes such as XMEs but not
others at a given epoch in the etiology of breast carci-
noma.
For further comprehension of the role played by XME
genes polymorphisms in breast carcinoma prognosis and
survival, we examined whether the five gene polymor-
phisms were associated with clinical pathological param-
eters, Overall survival (OVS) and Disease free Survival
(DFS) after treatment. None of the clinical pathological
parameters analyzed showed any statistically significant
differences by the genotypes of each of the five genes. This
is in accordance with results found by Chacko et al. for
other XME genes [10] (CYP1A1, GSTT1 and GSTM1) but
our results disagree with the findings of Han et al. which
showed that polymorphisms of XMEs genes such as
CYP1A1, CYP19 and CYP1B1 can influence clinical path-
ological features of breast carcinoma [9]. The influence of
XMEs genes polymorphisms on breast carcinoma progno-
sis is still poorly understood.
XME enzymes play a crucial role in the detoxification of
numerous products induced by cancer therapy [4] and
altered intra-tumoral gene coding for XMEs was suggested
as a potential molecular mechanism to explain reduced
treatment efficacy, tumor resistance [12], and conse-
quently survival and relapse after treatment. Several stud-
ies highlighted the role of XME gene polymorphisms such
as CYP1A1, CYP1B1, CYP2D6, mEH, GSTT1, GSTM1 and
NAT1 in treatment efficacy as well as survival after treat-
ment of breast carcinoma [10,12,13,31,41]. Previous
studies were largely carried out on small or heterogeneous
populations. In our previous data, the effect of GSTT1 and
GSTM1 gene deletions on survival after treatment of
breast carcinoma was not evident in the entire population
[13]. In the present study, mEH wild-type genotype was
significantly associated with decreased OVS in the same
Tunisian population of breast carcinoma patients. In
addition, the selection of axillary lymph node-positive
breast carcinoma allowed the appearance of a significant
association between decreased disease-free survival of
breast carcinoma and the mEH wild genotype. These
results were reinforced by the study of Fritz et al. indicat-
ing that mEH was identified as a predictor of the
tamoxifen (anticancer drug) response in breast carcinoma
[41]. Indeed, individuals carrying mEH wild-type geno-
type actively detoxify anticancer agents, reduce treatment
efficacy and consequently decrease survival after treat-
ment. No association was found with the four other gene
polymorphisms. However, there was an increase in DFS
for patients with axillary lymph node-negative carrying
NAT2 intermediate acetylator genotype.
In conclusion, this study suggests that CYP2D6, mEH and
NAT2 gene polymorphisms may be attractive susceptibil-
ity markers for breast carcinoma. A further interestingBMC Cancer 2008, 8:109 http://www.biomedcentral.com/1471-2407/8/109
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finding is that mEH and NAT2 gene polymorphisms rep-
resent a prognostic variable for predicting survival and
relapse after treatment in breast carcinoma patients.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
AK conceived of the study, conducted data analysis,
drafted the manuscript and with SG and EH carried out
the experiments. EH contributed to reviewing the manu-
script. NB and S-BA provided samples and clinical infor-
mation. LC conceived, designed and participated in the
data analysis and interpretation of the study. All authors
read and approved the final manuscript.
Acknowledgements
This work was supported by le Ministère de l'Enseignement Supérieur, de 
la Recherche scientifique et de la Technologie and by le Ministère de la 
Santé Publique de la République Tunisienne. We would like to thank Mr 
Rayhane Elkares for technical help and Mr Adel Rdissi for English revision.
References
1. Parkin DM: International variation.  Oncogene 2004, 23:6329-40.
2. Stewart SL, King JB, Thompson TD, Friedman C, Wingo PA: Cancer
mortality surveillance-United States, 1990–2000.  MMWR Sur-
veill Summ 2004, 53:1-108.
3. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics.  CA Can-
cer J Clin 2002, 52:23-47.
4. Bray F, Sankila R, Ferlay J, Parkin DM: Estimates of cancer inci-
dence and mortality in Europe in 1995.  Eur J Cancer 2002,
38:99-166.
5. Ben Ahmed S, Aloulou S, Bibi M, Landolsi A, Nouira M, Ben Fatma L,
Kallel L, Gharbi O, Korbi S, Khaïri H, Kraïem C: Breast cancer
detection in Tunisian women: an analysis of a hospital trial
involving 729 patients.  Santé Publique 2002, 14:231-41.
6. Dumitrescu RG, Cotaria I: Undrestanding breast cancer risk –
Where do we stand in 2005.  J Cell Mol Med 2005, 9:208-21.
7. Bennett IL, Gattas M, Teh BT: Genetic basis of breast cancer and
its clinical implications.  Aust N Z J Surg 1999, 69:95-105.
8. Rothman N, Wacholder S, Caporaso NE, Garcia-Closas M, Buetow
K, Fraumeni JF: The use of common genetic polymorphisms to
enhance the epidemiologic study of environmental carcino-
gens.  Biochim Biophys Acta 2001, 1471:C1-10.
9. Han W, Kang D, Park IA, Kim SW, Bae JY, Chung KW, Noh DY:
Associations between breast cancer susceptibility gene poly-
morphisms and clinicalpathological features.  Clin Cancer Res
2004, 10:124-30.
10. Chacko P, Joseph T, Mathew BS, Rajan B, Pillai MR: Role of xenobi-
otic metabolizing gene polymorphisms in breast cancer sus-
ceptibility and treatment outcome.  Mut Res 2005, 581:153-63.
11. Hurst R, Bao Y, Jemth P, Mannervik B, Williamson G: Phospholipid
hydroperoxide glutathione peroxidase activity of human glu-
tathione transferases.  Biochem J 1998, 332:97-100.
12. Biéche I, Girault I, Urbain E, Tozlu S, Lidereau R: Relationship
between intratumoral expression of genes coding for xeno-
biotic-metabolizing enzymes and benefit from adjuvant
tamoxifen in estrogen receptor alpha-positive postmeno-
pausal breast carcinoma.  Breast Cancer Res 2004, 6:R252-63.
13. Khedhaier A, Remadi S, Corbex M, Ben Ahmed S, Bouaouina N, Mes-
tiri S, Azaiez R, Helal AN, Chouchane L: Glutathione-S-trans-
ferases (GSTT1 and GSTM1) gene deletions in tunisians:
Susceptibility and prognostic implications in breast carci-
noma.  Br J Cancer 2003, 89:1502-7.
14. Olerup O, Zetterquist H: HLA-DR typing by PCR amplification
with sequence specific primers (PCR-SSP) in two hours: an
alternative to serological DR typing in clinical practice
including donor recipient matching in cadaveric transplanta-
tion.  Tissue Antigens 1992, 39:225-35.
15. Salama SA, Sierra-Torres CH, Oh HY, Hamada FA, Au WW: A mul-
tiplex-PCR/RFLP procedure for simultaneous CYP2E1,
mEH and GSTM1 genotyping.  Cancer Lett 1999, 143:51-6.
16. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA,
Goldstein JA: The major genetic defect responsible for the pol-
ymorphism of S-mephenytoin metabolism in humans.  J Biol
Chem 1994, 269:15419-22.
17. Lemos MC, Cabrita FJ, Silva HA, Vivan M, Placido F, Regateiro FJ:
Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and
susceptibility  to haematological neoplasias.  Carcinogenesis
1999, 20:1225-9.
18. De Jong MM, Nolte IM, Te Meerman GJ, Van der Graaf WT, Ooster-
wijk JC, Kleibeuker JH, Schaapveld M, de Vries EG: Genes other
than BRCA1 and BRCA2 involved in breast cancer suscepti-
bility.  J Med Genet 2002, 39:225-42.
19. Ladona MG, Abildua RE, Ladero JM, Roman JM, Plaza MA, Aqundez
JA, Muñoz JJ, Benítez J: CYP2D6 genotypes in spanish women
with breast cancer.  Cancer lett 1996, 99:23-8.
20. Lemos MC, Carrilho F, Rodrigues F, Coutinho E, Gomes L, Carval-
heiro M, Regateiro FJ: Genetic polymorphism of CYP2D6 influ-
ences susceptibility to papillary thyroid cancer.  Clin Endocrinol
2007, 67:180-3.
21. Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT: Meta-
analysis of studies of the CYP2D6 polymorphism in relation
to lung cancer and Parkinson's disease.  Pharmacogenetics 1998,
8:227-38.
22. Tucker AN, Tkaczuk KA, Lewis LM, Tomic D, Lim CK, Flaws JA: Pol-
ymorphisms in cytochrome P 450 3A5(CYP3A5) may be
associated with race and tumor characteristics, but not
metabolism and side effects of tamoxifen in breast cancer
patients.  Cancer lett 2005, 217:61-72.
23. Hanioka N, Kimura S, Meyer UA, Gonzalez FJ: The human
CYP2D6 locus associated with common genetic defect in
drug oxidation: a G1934A base change in intron 3 of a
mutant CYP2D6 allele results in an aberrant 3' splice recog-
nition site.  Am J Hum Genet 1990, 47:994-1001.
24. Wegman P, Vainikka L, Stal O, Nordenskjold B, Skoog L, Rutqvist LE,
Wingren S: Genotype of metabolic enzymes and the benefit of
tamoxifen in postmenopausal breast cancer patients.  Breast
cancer Res 2005, 7:R284-90.
25. Agundez JA: Cytochrome P450 gene polymorphism and can-
cer.  Curr Drug Metab 2004, 5:211-24.
26. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E: Allele and gen-
otype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an
Italian population.  Pharmacol Res 2004, 50:195-200.
27. Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed
MS: Allele and genotype frequencies of polymorphic cyto-
chromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydro-
pyrimidine dehydrogenase (DPYD) in the Egyptian
population.  Br J Clin Pharmacol 2002, 53:596-603.
28. Ruas JL, Lechner MC: Allele frequency of CYP2C19 in a Portu-
guese population.  Pharmacogenetics 1997, 7:333-5.
29. Ferreira PM, Medeiros R, Vasconcelos A, Costa S, Pinto D, Morais A:
Association between CYP2E1 polymorphisms and suscepti-
bility to prostate cancer.  Eur J Cancer Prev 2003, 12:205-11.
30. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ: Human microsomal
epoxide hydrolase: Genetic polymorphism and functional
expression in vitro of amine acid variants.  Hum Mol Genet 1994,
3:421-8.
31. London SJ, Smart J, Daly AK: Lung cancer risk in relation to
genetic polymorphisms of microsomal epoxide hydrolase
among African-Americains and Caucasians in Los Angeles
country.  Lung Cancer 2000, 28:147-55.
32. Jourenkova-Mironova N, Mitrunen K, Bouchardy C, Dayer P, Ben-
hamou S, Hirvonen A: High-activity microsomal epoxide hydro-
lase genotypes and the risk of oral, pharynx and larynx
cancers.  Cancer Res 2000, 60:534-6.
33. Baxter SW, Choong DY, Campbell IG: Microsomal epoxide
hydrolase polymorphism and susceptibility to ovarian can-
cer.  Cancer Lett 2002, 177:75-81.
34. Dupret JM, Rodrigues-Lima F: Structure and regulation of the
Drug-Metabolizing Enzymes Arylamine N-Acetyltrans-
ferases.  Curr Med Chem 2005, 12:311-8.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2008, 8:109 http://www.biomedcentral.com/1471-2407/8/109
Page 12 of 12
(page number not for citation purposes)
35. Alberg AJ, Daudt A, Huang HY, Hoffman SC, Comstock GW, Helzl-
souer KJ, Strickland PT, Bell DA: N-acetyltransferase-2 (NAT2)
genotypes, cigarette smoking and risk of breast cancer.  Can-
cer Detect Prev 2004, 28:187-93.
36. Kuo HW, Chou SY, Hu TW, Wu FY, Chen DJ: Urinary 8-hydroxy-
2'-deoxyguanosine (8-OHdG) and genetic polymorphisms in
breast cancer patients.  Mutat Res 2007, 631:62-8.
37. Chang-Claude J, Kropp S, Jager B, Bartsch H, Risch A: Differential
effect of NAT2 on the association between active and pas-
sive smoke exposure and breast cancer risk.  Cancer Epidemiol
Biomarkers Prev 2002, 11:698-704.
38. Costa S, Medeiros R, Vasconcelos A, Pinto D, Lopes C: A slow
acetylator genotype associated with an increased risk of
advanced cervical cancer.  J Cancer Res Clin Oncol 2002,
128:678-82.
39. Costa S, Pinto D, Morais A, Vasconcelos A, Oliveira J, Lopes C,
Medeiros R: Acetylation genotype and the genetic susceptibil-
ity to prostate cancer in a southern European population.
Prostate 2005, 64:246-52.
40. Narod SA: Modifiers of risk of hereditary breast and ovarian
cancer.  Nat Rev Cancer 2002, 2:113-23.
41. Fritz P, Murdter TE, Eichelbaum M, Siegle I, Weissert M, Zanger UM:
Microsomal epoxide hydrolase expression as a predictor of
tamoxifen response in primary breast cancer: a retrospec-
tive exploratory study with long-term follow-up.  J Clin Oncol
2001, 19:3-9.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/8/109/pre
pub